Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit

Company Overview - Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for cancer and viral infections [1][4] - The company utilizes a patented Decoy platform that activates both innate and adaptive immune responses through a multi-targeted approach [4] Key Events - Dr. Michael Newman, the Founder and Chief Scientific Officer, will serve as an Expert Speaker and Chair at the 6th Annual Cytokine-Based Drug Development Summit on May 15-16, 2025 [1][2] - Dr. Newman will present on "Pulsed Cytokine Delivery for Anti-Tumor Immunotherapy & its Impact on Toxicity & Efficacy" and lead discussions on pre-clinical models for cytokine drug development [2] Industry Recognition - The invitation for Dr. Newman to speak at the summit highlights his leadership in cytokine research and the growing recognition of Indaptus' novel approach in the industry [3] - The summit aims to bring together influential leaders to share knowledge and innovative strategies for overcoming challenges in cytokine drug development [3] Product Development - Indaptus' Decoy product candidates have shown promising results in pre-clinical studies, including activity against metastatic pancreatic and colorectal carcinomas, as well as chronic hepatitis B and HIV infections [4] - The Decoy platform has demonstrated reduced intravenous toxicity while effectively activating immune responses, leading to tumor eradication in combination with other therapies [4]